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What’s new? 
 Haemoglobin levels and differences in glucose metabolism at high altitude may influence 
the diagnostic performance of testing for diabetes using HbA1c. 
 We found that the relationship between HbA1c and fasting plasma glucose (FPG) differed 
markedly between high-altitude and sea-level areas. 
 The relationship between HbA1c and FPG was quadratic at sea level and linear at high 
altitude. 
 Corresponding FPG values for an HbA1c ≥ 48 mmol/mol (≥ 6.5%) cut-off point, used for 
the diagnosis of diabetes, were 6.6 and 14.8 mmol/l (120 and 266 mg/dl) at sea level and 
high altitude, respectively. 
 The sensitivity of HbA1c to detect abnormal FPG was 87.3% at sea level and 40.9% at 
high altitude. This suggests a limitation in the performance of HbA1c to diagnose diabetes 
at altitude. 
 
Abstract 
Aim  Higher haemoglobin levels and differences in glucose metabolism have been reported 
among high-altitude residents, which may influence the diagnostic performance of HbA1c. 
This study explores the relationship between HbA1c and fasting plasma glucose (FPG) in 
populations living at sea level and at an altitude of > 3000 m. 
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Methods  Data from 3613 Peruvian adults without a known diagnosis of diabetes from sea-
level and high-altitude settings were evaluated. Linear, quadratic and cubic regression models 
were performed adjusting for potential confounders. Receiver operating characteristic (ROC) 
curves were constructed and concordance between HbA1c and FPG was assessed using a 
Kappa index. 
Results  At sea level and high altitude, means were 13.5 and 16.7 g/dl (P > 0.05) for 
haemoglobin level; 41 and 40 mmol/mol (5.9% and 5.8%; P < 0.01) for HbA1c; and 5.8 and 
5.1 mmol/l (105 and 91.3 mg/dl; P < 0.001) for FPG, respectively. The adjusted relationship 
between HbA1c and FPG was quadratic at sea level and linear at high altitude. Adjusted 
models showed that, to predict an HbA1c value of 48 mmol/mol (6.5%), the corresponding 
mean FPG values at sea level and high altitude were 6.6 and 14.8 mmol/l (120 and 
266 mg/dl), respectively. An HbA1c cut-off of 48 mmol/mol (6.5%) had a sensitivity for high 
FPG of 87.3% (95% confidence interval (95% CI) 76.5 to 94.4) at sea level and 40.9% (95% 
CI 20.7 to 63.6) at high altitude. 
 
Conclusion The relationship between HbA1c and FPG is less clear at high altitude than at sea 
level. Caution is warranted when using HbA1c to diagnose diabetes mellitus in this setting. 
 
Introduction 
Nowadays, Type 2 diabetes mellitus is a global epidemic, and the prevalence is far from 
levelling off. The prevalence of diabetes has almost doubled in the last three decades and the 
chances of achieving the global target of halting the increase in prevalence by 2025 are < 1% 
[1]. Although originally identified by the presence of glucose in urine, glucose tests for the 
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diagnosis of Type 2 diabetes have been developed over the last century. The oral glucose 
tolerance test has been used for the diagnosis of Type 2 diabetes over the last three decades. 
However, this test is laborious for individuals, and thus, has been replaced by fasting plasma 
glucose (FPG) for use in both clinical settings and epidemiological studies. 
HbA1c had been established as the monitoring test of choice to evaluate medium-term 
diabetic control [2]. Several international societies, including the American Diabetes 
Association and World Health Organization (WHO) recommend using HbA1c as a diagnostic 
criterion for Type 2 diabetes in stable haematological circumstances, because it has several 
advantages over glucose tests, such as low intra-individual variation and the convenience of 
taking the test without fasting. However, this recommendation has been criticized because of 
the observed discordance between HbA1c and glucose tests, and biological variation in certain 
ethnic groups [3,4]. As such, alternative population-specific HbA1c cut-off points for the 
diagnosis of Type 2 diabetes have recently been proposed [5]. 
Changes in erythrocytes states, for example, due to folic acid deficiency and renal disease, 
erythrocyte lifespan and levels of haemoglobin can also influence HbA1c levels [6]. One of 
the mechanisms of adaptation in high-altitude settings is secondary polycythaemia (increase 
in haemoglobin levels) [7]. A common feature of many Latin American countries, where over 
the last two decades Type 2 diabetes-related mortality has been the highest worldwide [8], is 
a significant proportion of people living at high altitude. Over 30 million people currently 
reside in the Central American highlands, and in Peru, one third of the population live at 
altitude [9]. Indeed, secondary polycythaemia has been largely reported among Andean 
natives [10,11]. Additionally, differences in glucose metabolism have been reported among 
people residing at high altitude [12]. 
 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
In this study, we aim to explore and compare the relationship between HbA1c and FPG in 
populations living at high altitude and sea level. 
 
Methods 
Study settings and participants 
We identified eligible individuals from two Peruvian longitudinal population-based studies: 
the CRONICAS Cohort Study (n = 3601, baseline conducted in 2010–2011), and the rural 
Ayacucho population of the PERU MIGRANT Study (n = 200, baseline conducted in 2007–
2008). The CRONICAS Cohort Study aimed to assess the prevalence and incidence of 
cardiometabolic and pulmonary conditions at four sites: Lima, highly urban, sea level; 
Tumbes, semi-urban, sea level; and two high-altitude locations (3825 m above sea level), 
rural and urban Puno. All participants were aged 35 years or older and full-time residents in 
the area. The PERU MIGRANT Study was designed to investigate differences in 
cardiovascular disease risk factors between rural-to-urban migrant and non-migrant groups. 
This study was performed in participants aged 30 years and over from a rural site in 
Ayacucho, located at 2900–3100 m above sea level, an urban site in Lima, and rural-to-urban 
migrants from Ayacucho currently residing in Lima. In both studies, participants were sex- 
and age-stratified, a single-stage random sampling was used, and only one participant per 
household was enrolled. The studies are described in detail elsewhere [13,14]. 
The original pooled dataset had 3801 cases. We excluded 187 individuals with self-reported 
diagnosis of diabetes or use of anti-diabetic medications. In addition, one person was 
excluded during regression analysis because that individual was an influential point. The final 
number of people included in this analysis was 3613. 
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Participants were classified into two geography-based categories: (1) sea-level population 
(those from Lima and Tumbes), and (2) high-altitude population (those from Ayacucho and 
Puno). 
 
Study variables 
We evaluated clinical variables, including BMI, hypertension (systolic blood pressure 
≥ 140 mmHg or diastolic blood pressure ≥ 90 mmHg or current use of antihypertensive 
medications), and current smoking status (self-report of having smoked at least one cigarette 
in the last 30 days). We also explored sociodemographic variables, such as wealth index 
based on asset possessions [15] and educational level (primary or less, secondary and higher). 
Besides FPG (mmol/l) and HbA1c (mmol/mol; %), additional laboratory variables included 
lipid measurements (total cholesterol, triglycerides, HDL-C and Friedewald-estimated 
LDL-C, in mg/dl), and haematological parameters, such as total haemoglobin (g/dl), mean 
corpuscular volume (fl/red blood cell), mean corpuscular haemoglobin (pg/cell) and mean 
corpuscular haemoglobin concentration (g/dl). HbA1c was measured using high-performance 
liquid chromatography (HPLC, D10-BIORAD, Germany), which is traceable to the Diabetes 
Control and Complications Trials reference study as certified by the National 
Glycohemoglobin Standardization Program. 
 
Statistical analysis 
For descriptive purposes, study variables were compared between sea-level and high-altitude 
settings using analysis of variance, chi-squared or Fisher’s exact tests. Linear, quadratic and 
cubic regression models were performed to assess the relationship between HbA1c and FPG, 
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crude and adjusted by age, sex, education, wealth, BMI and total haemoglobin. Models were 
performed separately for each sea-level and high-altitude subgroup. 
Beta coefficients and 95% confidence intervals (95% CI) were calculated for FPG, squared-
FPG and/or cubic-FPG. Maximum likelihood optimization (Newton–Raphson) and robust 
variance estimations [16] were used in these models to compensate for heteroscedasticity and 
non-normality. Information from Wald’s test and Bayesian information criteria helped select 
the best models. 
We evaluated diagnostic performance for diabetes and prediabetes in the sea-level and high-
altitude subgroups using FPG as the gold standard. We used the cut-off points recommended 
by the American Diabetes Association for HbA1c (normal < 39 mmol/mol, < 5.7%; 
prediabetes 39 to < 48 mmol/mol, 5.7 to < 6.5%; diabetes ≥ 48 mmol/mol, ≥ 6.5%) and FPG 
(normal < 5.6 mmol/l; prediabetes 5.6–6.9 mmol/l; diabetes ≥ 7.0 mmol/l). We evaluated 
sensitivity, specificity, positive predictive value, negative predictive value and likelihood 
ratios of HbA1c, and receiver operating characteristic (ROC) curves. 
Finally, we compared concordance between diagnosis by HbA1c and FPG using a Kappa 
index. All analyses were conducted using Stata/IC v. 12 (Stata Corp, College Station, TX, 
USA). Ethical approval was obtained for the original studies. 
 
Results 
In total, 3613 individuals were included in the analysis: Lima, n = 1036; Tumbes, n = 963; 
Ayacucho, n = 200; and Puno, n = 1414. Haemoglobin levels were significantly lower in 
individuals at sea level (13.5 ± 1.4 g/dl) than those at high altitude (16.7 ±1.9 g/dl) 
(P < 0.001). Mean HbA1c was 41 mmol/mol (5.9 ± 0.88%) at sea level, and 40 mmol/mol 
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(5.8 ± 0.48%) at high altitude. Individuals at sea level had higher mean FPG 
(5.3 ± 1.4 mmol/l) compared with those from high altitude (4.9 ± 0.9 mmol/l) (P < 0.001). 
The cardiovascular risk factor profile, in terms of adiposity, lipid markers, hypertension and 
smoking status, was poorer among those living at sea level. Diabetes, defined both by HbA1c 
and FPG, was more prevalent at sea level than high altitude. In both high-altitude and sea-
level settings, the estimates of HbA1c-defined diabetes were three times higher than those 
based on FPG. We had haematological parameters from one site at high altitude (Ayacucho, 
n = 167). Levels of mean haematocrit were 48.5 ± 4.1; mean corpuscular volume was 
94.9 ± 4.9 fl/red blood cell; mean corpuscular haemoglobin was 31.2 ± 1.7 pg/cell; and mean 
corpuscular haemoglobin concentration was 32.8 ± 1.2 g/dl (Table 1). 
In both crude and adjusted models, we found differences between predictions of HbA1c by 
FPG at sea level and high altitude (Figs 1 and 2). Whereas HbA1c and FPG showed a non-
linear, quadratic relationship at sea level, we found a linear association at high altitude 
(Table S1). Differences in relationship patterns and intercept values (3.9 for high altitude, 4.6 
for sea level) display notable differences in the shape of each curve (Fig. 1). This effect has a 
repercussion on values for diagnosis: to predict an HbA1c value of 48 mmol/mol (6.5%), 
mean FPG values of 6.7 and 14.8 mmol/l were needed at sea level and high altitude, 
respectively. 
Among those with diabetes, at sea level, the number of individuals diagnosed by HbA1c was 
13.5 times greater than diagnosed by FPG only (108 vs. 8), and this relationship was 4.6 
times greater at high altitude (60 vs. 13). Individuals diagnosed by HbA1c only were older, 
but metabolically healthier at high altitude than at sea level. Similar results were found 
among individuals diagnosed by FPG, and by the combination of HbA1c and FPG (Table 2). 
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Using HbA1c instead of FPG to diagnose diabetes increased the number of cases by 159% at 
sea level and 215% at high altitude. Finally, when evaluating the agreement between 
diagnosis of diabetes and prediabetes by HbA1c and FPG, we found poor agreement at sea 
level (Kappa = 0.19) and at high altitude (Kappa = 0.04) (Table 3). 
The sensitivity of an HbA1c cut-off value 48 mmol/mol (6.5%) for diabetes diagnoses, using 
FPG as a gold standard, was much higher in the sea-level groups (87.3%) than in the high-
altitude groups (40.9%), with specificities of 94.2% and 95.0%, respectively. Positive 
likelihood ratios were 15.1 and 8.1, respectively. Sensitivities for diagnosis of prediabetes 
were similar, 74.7% and 71.4% in the sea-level and high-altitude groups, respectively 
(Table 4). ROC areas for sea level (0.95) and high altitude (0.74) were significantly different 
(chi
2
(1) = 9, P < 0.01) using HbA1c standard cut-points and FPG as the gold standard of 
diabetes (Fig. S1). ROC areas for sea level (0.68) and high altitude (0.57) were also 
significantly different (chi
2
(1) = 12, P < 0.001) using HbA1c standard cut-points and FPG as 
the gold standard of prediabetes (Fig. S2). 
The prevalence of diabetes is higher when HbA1c is used (≥ 48 mmol/mol; ≥ 6.5%) rather 
than FPG (≥ 7.0 mmol/l) for sea-level populations (diabetes prevalence of 12.3% with HbA1c 
and 6.5% with FPG) and high-altitude populations (diabetes prevalence of 7.9% with HbA1c 
and 3.8% with FPG) (Table S2). 
 
Discussion 
In this study, we found that the relationship between HbA1c and FPG differed markedly 
between populations living at high altitude and sea level. Using current recommended HbA1c 
cut-off points for the diagnosis of diabetes (≥ 48 mmol/mol, ≥ 6.5%), our models showed a 
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discrepancy of up to 7.8 mmol/l units of FPG. In other words, corresponding FPG values for 
such HbA1c cut-off point were 6.7 and 14.8 mmol/l at sea level and high altitude, 
respectively. This translated into major discrepancies in diagnostic performance, as shown by 
differences in the sensitivity of HbA1c at sea level (89%) compared with at high altitude 
(41%). In terms of new cases of diabetes, greater discordance was observed in high-altitude 
settings, which was confirmed by the poor agreement found. Taken together, our findings 
show that high altitude is another setting in which HbA1c might not be appropriate when used 
as a diagnostic tool for Type 2 diabetes. 
Discordance between FPG and HbA1c has been reported in American, European and Asian 
populations, as well as in older and female individuals. However, this is the first study 
reporting discordance in Andean populations. Differences in the glycation process, of genetic 
or adaptive origin, have been shown to play a significant role in inter-individual variance by 
causing abnormally high or low levels of HbA1c for a given plasma glucose level [18]. 
However, other physiological or environmental pathways may contribute to discordance 
observed between FPG and HbA1c in our study settings. 
 
We observed that FPG was, on average, 0.4 mmol/l higher at sea-level sites than at high-
altitude sites, yet mean HbA1c was similar in both study groups. Glucose metabolism has 
been shown to differ at altitude; for instance, an association between polycythaemia and 
glucose intolerance has previously been described in an Andean population [12]. A study in 
rats showed that exposure to hypobaric hypoxia is associated with reduced insulin release due 
to inhibition of corticotrophin-releasing hormone [19]. This has also been replicated in 
clinical research; a recent publication by our group found that a 5% decrease in 
oxyhaemoglobin saturation was strongly associated with a HbA1c value ≥ 48 mmol/mol 
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(≥ 6.5%) (Miele C et al. personal communication). It is possible that these processes of 
relative intolerance lead to a serum glucose level that is not represented by a FPG test 
obtained in a fasting state, but is identified by HbA1c. 
We hypothesize that the discrepancy observed in our study might be partially explained by an 
increase in haemoglobin production. An erythropoietin-driven increase in haemoglobin 
production is the most important mechanism of adaptation and acclimatization seen at 
altitude, especially in the Andes [20,21]. This observation was further confirmed in our study, 
because we found significantly higher mean haemoglobin levels at high altitude than at sea 
level. Increased erythropoiesis due to other causes, such as intravenous iron or 
erythropoietin-stimulating agents, has also been shown to influence HbA1c levels [22–24]. In 
high-altitude native populations, the utilization of iron appears to be 25% greater than in 
people from sea-level settings [25], and higher HbA1c values have been reported in 
individuals with iron deficiency [26,27]. Haemoglobin levels may affect the extent of 
glycation, however, the effect of altitude on lifespan remains unclear [28]. Our 
haematological data were limited and thorough evaluation of haematological parameters in 
relationship to glucose and other metabolic markers will add to this understanding. Another 
potential mechanism to explain our observations might be related to haemoglobin glycation 
itself at altitude, although the literature is limited in this field. Indeed, many of the 
mechanisms presented deserve to be fully studied in high-altitude settings. 
Mounting evidence from observational and controlled clinical trials has demonstrated a 
strong association between HbA1c levels and retinopathy and other microvascular 
complications of diabetes. Moreover, HbA1c is also associated with increased risk of 
cardiovascular disease, even in individuals without diabetes [29]. As such, the role of HbA1c 
as a key biomarker is undeniable. Yet, the discordance between FPG and HbA1c at altitude 
observed in our study, particularly in high-altitude settings, merits further and deeper scrutiny 
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because the number of people classified as having diabetes would treble if HbA1c was used as 
a diagnosis tool. This discrepancy between HbA1c and FPG has recently been highlighted in a 
global data-pooling study signalling difficulties for monitoring of diabetes targets at a policy 
level [30]. Consequently, many individuals residing at high altitude, who were shown to have 
a more favourable cardiometabolic risk profile than those residing at sea level, would initiate 
glucose-lowering medications and be exposed to the unnecessary harm associated with such 
treatments. Given the large populations living at high altitude and the rising prevalence of 
diabetes worldwide, especially in the southern hemisphere, inappropriate prescription of anti-
diabetic medications might lead to inefficient public health policies in countries with limited 
economic resources. 
 
This study has benefited from leveraging data from well-defined population-based studies 
and relatively large sample sizes. Peru has a particular geographical distribution characterized 
by a large variety of climates and altitudes. The CRONICAS Cohort Study and the PERU 
MIGRANT Study cohorts are unique in that they have a relatively large proportion of 
individuals living at high altitude, > 3000 m above sea level, where increases in haemoglobin 
levels are mostly observed. Despite this, our study did not have data on oral glucose tolerance 
test, the gold standard test used for diabetes research, multiple FPG readings over time to 
more accurately represent glucose levels in people with diabetes, or a detailed evaluation of 
all haematological markers in all sites. The cross-sectional approach of this study precludes 
the ascertainment of causal relationships; therefore, longitudinal studies are better placed to 
explore the long-term consequences of the discordant patterns reported, particularly in terms 
of progression of diabetes-related complications. Prospective evaluations are also required to 
evaluate clinical and economic consequences that may result from modification of current 
diagnostic criteria. 
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Conclusions 
These findings provide unique evidence that the relationship between HbA1c and FPG differs 
considerably between sea-level and high-altitude settings. Our models show that an HbA1c of 
48 mmol/mol (6.5%) would correspond to different FPG levels in each setting, as shown by a 
discrepancy of up to 7.8 mmol/l. Such a substantial difference hampers potential strategies 
for expanding diabetes diagnosis and public health planning in high-altitude settings, and 
therefore FPG and the oral glucose tolerance test should be used as diagnostic criteria under 
these circumstances. 
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Additional Supporting Information may be found in the online version of this article: 
Table S1 Linear, quadratic and cubic regression models for HbA1c using glucose-like 
predictor (crude and adjusted models). 
Table S2 Distribution of diabetes and prediabetes at sea level and high altitude considering 
HbA1c or FPG standard cut-off points and including cases of diabetes diagnosed by physician 
and pharmacological treatment. 
Figure S1 Comparison between ROC curves at sea level (blue) and high altitude (red), for 
HbA1c standard cut-off points using FPG as the gold standard of diabetes. 
Figure S2 Comparison between ROC curves at sea level (blue) and high altitude (red), for 
HbA1c standard cut-off points using FPG as the gold standard of prediabetes. 
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FIGURE 1 Graphical representation of the quadratic model (sea level) and linear model (high altitude) for 
HbA1c (dependent variable) and fasting plasma glucose (independent variable), crude and adjusted by age, sex, 
education, wealth, BMI and total haemoglobin levels. After comparison of linear, quadratic and cubic models of 
the relationship between HbA1c and fasting plasma glucose, a quadratic adjusted model was selected as the best 
for people at sea level, and a linear adjusted model was selected as the best for people at high altitude 
(Table S1). The red line was established at an HbA1c value of 48 mmol/mol (6.5%) to represent the current 
recommended diagnostic cut-point for diabetes [17]. 
FIGURE 2 Amplification of the zone near to an HbA1c value of 48 mmol/mol (6.5%) in the graphical 
representation of the quadratic model (sea level) and linear model (high altitude) for HbA1c (dependent variable) 
and fasting plasma glucose (independent variable) both crude and adjusted by age, sex, education, wealth, BMI 
and total haemoglobin. The red line was established at a HbA1c value of 48 mmol/mol (6.5%) to indicate the 
standard diagnostic cut-point for diabetes [17].  
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Table 1 Characteristics of study participants at sea-level and high-altitude settings 
Variable Total (n = 3613) Sea level (n = 1999) 
High altitude 
(n = 1614) 
P* 
Sociodemographic 
Age (mean ± SD) 3611 55.2 ± 12.7 55.0 ± 13.0 0.77 
Male, n (%) 3610 986 (49.3) 770 (47.8) 0.36 
Wealth index (mean ± SD) 3613 251.9 ± 153.8 167.9 ± 161.8 < 0.001 
Education 
   
< 0.001 
 
Primary or less, n (%) 1709 971 (48.6) 738 (45.7) 
 
 
Secondary, n (%) 1137 707 (35.4) 430 (26.7) 
 
 
Higher, n (%) 764 319 (16.0) 445 (27.6) 
 
Cardiovascular risk factors 
BMI (kg/m
2
, mean ± SD) 3248 28.3 ± 4.6 25.9 ± 4.2 < 0.001 
Waist circumference, cm (mean ± SD) 3243 93.2 ± 10.4 86.6 ± 12.1 < 0.001 
Total cholesterol (mean ± SD) 2947 202.4 ± 38.7 194.7 ± 40.8 < 0.001 
Triglycerides median (IQR) 3147 139 (97) 125 (83) < 0.001 
HDL-C (mean ± SD) 2947 40.9 ± 11.5 43.0 ± 11.3 < 0.001 
LDL-C (mean ± SD)
†
 200 – 85.7 ± 27.1 
 
Hypertension, n (%) 3047 291 (15.0) 106 (9.6) < 0.001 
Current smoker, n (%) 3610 268 (13.4) 130 (8.1) < 0.001 
Haematological variables 
Haemoglobin (mean ± SD) 3146 13.5 ± 1.4 16.7 ± 1.9 < 0.001 
Mean corpuscular volume, fl/red blood 
cell
†
 
167 – 94.9 ± 4.9 
 
Mean corpuscular haemoglobin, pg/cell
†
 167 – 31.2 ± 1.7 
 
Mean corpuscular haemoglobin 
concentration, g/dl
†
 
167 – 32.8 ± 1.2 
 
Diabetes-related markers 
HbA1c (mean mmol/mol) 3146 41 40 0.10 
HbA1c (mean % ± SD)  5.9 ± 0.88 5.8 ± 0.48  
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Fasting plasma glucose (mean 
mmol/l ± SD) 
3146 5.3 ± 1.4 4.9 ± 0.9 < 0.001 
Diabetes diagnosed by HbA1c 
‡
 
   
< 0.001 
 
Normal, n (%) 1227 789 (40.9) 438 (36.0) 
 
 
Prediabetes, n (%) 1687 978 (50.6) 709 (58.3) 
 
 
Diabetes, n (%) 232 163 (8.5) 69 (5.7) 
 
Diabetes diagnosed by FPG
§
 
   
< 0.001 
 
Normal, n (%)* 2493 1433 (74.3) 1060 (87.2) 
 
 
Prediabetes, n (%)* 568 434 (22.5) 134 (11.0) 
 
 
Diabetes, n (%)* 85 63 (3.3) 22 (1.8) 
 
*ANOVA one-way for mean differences; Kruskal–Wallis or median differences; chi square for distribution 
differences. 
†
Only available for Ayacucho. 
‡
Prediabetes and diabetes were diagnosed using the American Diabetes Association recommended HbA1c cut-
off point: diabetes, HbA1c ≥ 48 mmol/mol (≥ 6.5%); prediabetes, ≥ 48 mmol/mol (6.5%) > HbA1c 
≥ 39 mmol/mol (≥ 5.7%); normal, HbA1c < 39 mmol/mol (< 5.7%). 
§
Prediabetes and diabetes were diagnosed using the American Diabetes Association recommended FPG cut-off 
point: diabetes, FPG ≥ 7.0 mmol/l; prediabetes, 7.0 mmol/l > FPG ≥ 5.6 mmol/l; normal: FPG < 5.6 mmol/l. 
FPG, fasting plasma glucose. 
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Table 2 Clinical characteristics of individuals with diagnosis of diabetes by different criteria* 
  Overall Sea-level population High-altitude population 
Variable HbA1c only 
HbA1c and 
FPG 
FPG only HbA1c only 
HbA1c and 
FPG 
FPG only HbA1c only 
HbA1c and 
FPG 
FPG only 
n
†
 168 64 21 108 55 8 60 9 13 
Age (mean ± SD) 60.4 ± 12.8 57.2 ± 10.5 58.4 ± 12.3 59.1 ± 12.9 57.0 ± 10.3 53.8 ± 14.1 62.7 ± 12.2 58.7 ± 12.0 61.3 ± 10.6 
Male, n (%) 59 (35.1) 26 (40.6) 12 (57.1) 42 (38.9) 23 (41.8) 5 (62.5) 17 (28.3) 3 (33.3) 7 (53.9) 
BMI (kg/m
2
) 29.6 ± 6.0 30.6 ± 5.1 28.5 ± 6.1 30.7 ± 5.8 30.9 ± 5.0 33.0 ± 7.8 27.6 ± 5.9 28.9 ± 5.3 25.7 ± 2.4 
Waist 
circumference 
(mean ± SD) 
95.1 ± 13.4 99.0 ± 9.2 94.4 ± 15.0 98.3 ± 11.0 99.7 ± 11.3 104.9 ± 17.5 89.3 ± 15.4 95.0 ± 13.5 87.9 ± 8.9 
Total cholesterol 
(mean ± SD) 
208.8 ± 42.9 218.0 ± 39.4 220.0 ± 42.3 211.8 ± 39.4 217.7 ± 40.8 236.6 ± 43.2 201.9 ± 49.7 219.5 ± 29.9 209.6 ± 39.9 
Triglycerides 
median (IQR) 
149 (101) 184 (100) 112 (81) 148 (97) 183 (108) 138 (66) 149 (105) 185 (96) 111 (84) 
HDL-C 
(mean ± SD) 
39.0 ± 10.3 38.6 ± 10.6 50.1 ± 15.3 38.7 ± 9.8 38.5 ± 11.1 48.1 ± 17.8 39.8 ± 11.6 39.4 ± 7.8 51.3 ± 14.2 
Hypertension, n 34 (22.1) 20 (31.8) 2 (9.5) 28 (25.9) 20 (36.4) 2 (25.0) 6 (13.0) 0 (0) 0 (0) 
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(%) 
Current smoker, 
n (%) 
23 (13.7) 11 (17.2) 4 (19.1) 16 (14.8) 10 (18.2) 2 (25.0) 7 (11.7) 1 (11.1) 2 (15.4) 
Haemoglobin 
(mean ± SD) 
14.5 ± 2.6 14.3 ± 2.2 16.0 ± 2.0 13.2 ± 1.7 13.6 ± 1.1 14.3 ± 0.98 16.9 ± 2.3 18.5 ± 2.5 17.0 ± 1.8 
*Diagnosed by HbA1c only: HbA1c ≥ 48 mmol/mol (≥ 6.5%) and FPG < 7.0 mmol/l; diagnosed by FPG only: HbA1c < 48 mmol/mol (< 6.5%) and FPG ≥ 7.0 mmol/l; 
diagnosed by both: HbA1c ≥ 48 mmol/mol (≥ 6.5%) and FPG ≥ 7.0 mmol/l. 
†
Of a total 3613 people in the study, we excluded those without diabetes (n = 2892) and those without complete data to evaluate diabetes status (HbA1c and FPG, n = 468), 
therefore data from n = 253 people is included. 
Entries in bold represent P < 0.05 in comparisons between sea-level and high-altitude populations. For categorical variables (%) we used Fisher's exact test (2 × 3 cross 
table). For continuous variables (means) we used one-way ANOVA, comparing each criterion by altitude (separately). For non-normal variables (medians) we used Kruskal–
Wallis test, comparing each criterion by altitude (separately). 
FPG, fasting plasma glucose. 
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Table 3 Concordance of diabetes and prediabetes diagnostics at sea level and high altitude settings considering HbA1c or FPG standard cut-points 
  
Sea-level population High-altitude population 
Test  
HbA1c HbA1c 
 
Normal Prediabetes Diabetes Total Normal Prediabetes Diabetes Total 
Fasting 
plasma 
glucose 
Normal 692 691 50 1433 402 619 38 1059 
Prediabetes 95 281 58 434 32 80 22 134 
Diabetes 2 6 55 63 4 9 9 22 
Total* 789 978 163 1930 438 708 69 1215 
*Of a total of 3613 people in the study, we excluded those without complete data to evaluate diabetes status (HbA1c and FPG, n = 468), therefore, data from n = 3145 people 
are included. 
Diagnostic criteria for HbA1c: diabetes, HbA1c ≥ 48 mmol/mol (≥ 6.5%); prediabetes, ≥ 48 mmol/mol (6.5%) > HbA1c ≥ 39 mmol/mol (≥ 5.7%); normal: 
HbA1c < 39 mmol/mol (< 5.7%). 
Diagnostic criteria for FPG: diabetes, FPG ≥ 7.0 mmol/l; prediabetes, 7.0 > FPG ≥ 5.6 mmol/l; normal, FPG < 5.6 mmol/l. 
Concordance at sea-level settings: kappa = 0.19, expected agreement = 42.0%; agreement = 53.3%. 
Concordance at high-altitude settings: kappa = 0.04, expected agreement = 38.0%; agreement = 40.4%. 
FPG, fasting plasma glucose. 
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Table 4 Diagnostic test characteristics for HbA1c standard cut-points using FPG as the gold standard 
  Sea-level population 
(n = 1930)* 
High-altitude population 
(n = 1215)* 
 Test % 95% CI % 95% CI 
Diabetes, HbA1c 
≥ 48 mmol/mol (≥ 6.5%) 
Sensitivity 87.3 (76.5–94.4) 40.9 (20.7–63.6) 
Specificity 94.2 (93.1–95.2) 95.0 (93.6–96.1) 
PPV 51.2 (46.1–56.3) † 25.3 (16.2–37.2) † 
NPV 99.1 (98.2–99.5)† 97.5 (96.5–98.2) † 
LR+ 15.1 (12.3–18.5) 8.1 (4.7–14.2) 
LR- 0.14 (0.07–0.26) 0.62 (0.44–0.88) 
Prediabetes, HbA1c 
≥ 39 mmol/mol (≥ 5.7%) and 
< 48 mmol/mol (< 6.5%) 
Sensitivity 74.7 (70.0-79.0) 71.4 (62.1–79.6) 
Specificity 50 (47.4–52.7) 39.4 (36.4–42.4) 
PPV 32.1 (30.4–33.8) † 13.8 (12.4–15.4) † 
NPV 86.2 (83.9–88.3) † 91.0 (88.2–93.2) † 
LR+ 1.5 (1.4–1.6) 1.2 (1.1–1.3) 
LR– 0.51 (0.42–0.61) 0.73 (0.54–0.98) 
*Of a total 3613 people in the study, we excluded those without complete data to evaluate diabetes status 
(HbA1c and FPG, n = 468), therefore data from n = 3145 people are included. 
†
Values and confidence intervals are based on likelihood ratios, using prevalence estimated in this study (using 
explained FPG cut-off points). Diabetes sea level = 6.5%; diabetes high altitude = 4%; prediabetes sea 
level = 24%; prediabetes high altitude = 12%. 
The gold standard for diabetes is defined as FPG ≥ 7.0 mmol/l and for prediabetes 7.0 mmol/l > FPG 
≥ 5.6 mmol/l. 
95% CI, 95% confidence interval; FPG, fasting plasma glucose; PPV, positive predictive value; NPV, negative 
predictive value; LR+, ; LR–, . 
 
 
 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
 
 
 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
 
 
 
 
